Multi-action Pt(IV) anticancer agents; do we understand how they work?
- 15 November 2018
- journal article
- review article
- Published by Elsevier BV in Journal of Inorganic Biochemistry
- Vol. 191, 77-84
- https://doi.org/10.1016/j.jinorgbio.2018.11.008
Abstract
No abstract availableKeywords
Funding Information
- Israel Science Foundation
This publication has 65 references indexed in Scilit:
- Mitaplatin Increases Sensitivity of Tumor Cells to Cisplatin by Inducing Mitochondrial DysfunctionMolecular Pharmaceutics, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer ChemotherapyMetal-Based Drugs, 2010
- Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetateProceedings of the National Academy of Sciences of the United States of America, 2009
- Understanding the Warburg Effect: The Metabolic Requirements of Cell ProliferationScience, 2009
- Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric CancerCancer Research and Treatment, 2009
- Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatinMolecular Cancer, 2008
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- The Hallmarks of CancerCell, 2000